RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Brookline Capital Markets initiated coverage of Exelixis (NASDAQ:EXEL) with a buy rating, highlighting the company's revenue ...

Fintel reports that on December 17, 2024, B of A Securities downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Buy to ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying ...

According to Benzinga Pro, Exelixis's peer group average for short interest as a percentage of float is 4.93%, which means ...

Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...

Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding ...

Equities research analysts at Zacks Research boosted their Q4 2024 earnings per share (EPS) estimates for Exelixis in a ...

As previously reported, BofA downgraded Exelixis (EXEL) to Neutral from Buy with a price target of $39, up from $35. The stock price has gained ...